123 related articles for article (PubMed ID: 9972690)
1. Cerebrolysin ameliorates performance deficits, and neuronal damage in apolipoprotein E-deficient mice.
Masliah E; Armasolo F; Veinbergs I; Mallory M; Samuel W
Pharmacol Biochem Behav; 1999 Feb; 62(2):239-45. PubMed ID: 9972690
[TBL] [Abstract][Full Text] [Related]
2. Beneficial effects of a neurotrophic peptidergic mixture persist for a prolonged period following treatment interruption in a transgenic model of Alzheimer's disease.
Rockenstein E; Ubhi K; Pham E; Michael S; Doppler E; Novak P; Inglis C; Mante M; Adame A; Alvarez XA; Moessler H; Masliah E
J Neurosci Res; 2011 Nov; 89(11):1812-21. PubMed ID: 21793038
[TBL] [Abstract][Full Text] [Related]
3. Neurodegeneration and cognitive impairment in apoE-deficient mice is ameliorated by infusion of recombinant apoE.
Masliah E; Samuel W; Veinbergs I; Mallory M; Mante M; Saitoh T
Brain Res; 1997 Mar; 751(2):307-14. PubMed ID: 9099820
[TBL] [Abstract][Full Text] [Related]
4. Neurotrophic effects of Cerebrolysin in animal models of excitotoxicity.
Veinbergs I; Mante M; Mallory M; Masliah E
J Neural Transm Suppl; 2000; 59():273-80. PubMed ID: 10961439
[TBL] [Abstract][Full Text] [Related]
5. Role of apolipoprotein E receptors in regulating the differential in vivo neurotrophic effects of apolipoprotein E.
Veinbergs I; Van Uden E; Mallory M; Alford M; McGiffert C; DeTeresa R; Orlando R; Masliah E
Exp Neurol; 2001 Jul; 170(1):15-26. PubMed ID: 11421580
[TBL] [Abstract][Full Text] [Related]
6. Cerebrolysin in Alzheimer's disease.
Antón Álvarez X; Fuentes P
Drugs Today (Barc); 2011 Jul; 47(7):487-513. PubMed ID: 22013558
[TBL] [Abstract][Full Text] [Related]
7. The neuroprotective effects of Cerebrolysin in a transgenic model of Alzheimer's disease are associated with improved behavioral performance.
Rockenstein E; Adame A; Mante M; Moessler H; Windisch M; Masliah E
J Neural Transm (Vienna); 2003 Nov; 110(11):1313-27. PubMed ID: 14628195
[TBL] [Abstract][Full Text] [Related]
8. Cerebrolysin decreases amyloid-beta production by regulating amyloid protein precursor maturation in a transgenic model of Alzheimer's disease.
Rockenstein E; Torrance M; Mante M; Adame A; Paulino A; Rose JB; Crews L; Moessler H; Masliah E
J Neurosci Res; 2006 May; 83(7):1252-61. PubMed ID: 16511867
[TBL] [Abstract][Full Text] [Related]
9. Effects of Cerebrolysin on amyloid-beta deposition in a transgenic model of Alzheimer's disease.
Rockenstein E; Mallory M; Mante M; Alford M; Windisch M; Moessler H; Masliah E
J Neural Transm Suppl; 2002; (62):327-36. PubMed ID: 12456076
[TBL] [Abstract][Full Text] [Related]
10. A double-blind, placebo-controlled, multicenter study of Cerebrolysin for Alzheimer's disease.
Bae CY; Cho CY; Cho K; Hoon Oh B; Choi KG; Lee HS; Jung SP; Kim DH; Lee S; Choi GD; Cho H; Lee H
J Am Geriatr Soc; 2000 Dec; 48(12):1566-71. PubMed ID: 11129744
[TBL] [Abstract][Full Text] [Related]
11. Marked hippocampal neuronal damage without motor deficits after mild concussive-like brain injury in apolipoprotein E-deficient mice.
Han SH; Chung SY
Ann N Y Acad Sci; 2000 Apr; 903():357-65. PubMed ID: 10818526
[TBL] [Abstract][Full Text] [Related]
12. [ApoE genotype and efficacy of neurotrophic and cholinergic therapy in Alzheimer's disease].
Gavrilova SI; Kolykhalov IV; Korovaĭtseva GI; Zharikov GA; Kalyn IaB; Selezneva ND
Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(4):27-34. PubMed ID: 15880838
[TBL] [Abstract][Full Text] [Related]
13. [4th International Symposium. "Cerebrolysin: pharmacological effects and role in clinical practice"].
Gomazkov OA
Zh Nevrol Psikhiatr Im S S Korsakova; 2002; 102(9):69-70. PubMed ID: 12378888
[No Abstract] [Full Text] [Related]
14. Positive effects of cerebrolysin on electroencephalogram slowing, cognition and clinical outcome in patients with postacute traumatic brain injury: an exploratory study.
Alvarez XA; Sampedro C; Pérez P; Laredo M; Couceiro V; Hernández A; Figueroa J; Varela M; Arias D; Corzo L; Zas R; Lombardi V; Fernández-Novoa L; Pichel V; Cacabelos R; Windisch M; Aleixandre M; Moessler H
Int Clin Psychopharmacol; 2003 Sep; 18(5):271-8. PubMed ID: 12920387
[TBL] [Abstract][Full Text] [Related]
15. Increased density of glutamate receptor subunit 1 due to Cerebrolysin treatment: an immunohistochemical study on aged rats.
Eder P; Reinprecht I; Schreiner E; Skofitsch G; Windisch M
Histochem J; 2001; 33(11-12):605-12. PubMed ID: 12197668
[TBL] [Abstract][Full Text] [Related]
16. Biochemical and cognitive studies of apolipoprotein-E-deficient mice.
Gordon I; Genis I; Grauer E; Sehayek E; Michaelson DM
Mol Chem Neuropathol; 1996; 28(1-3):97-103. PubMed ID: 8871947
[TBL] [Abstract][Full Text] [Related]
17. [Pharmacological approaches to the therapy of Alzheimer's disease].
Gavrilova SI
Vestn Ross Akad Med Nauk; 2006; (9-10):30-4. PubMed ID: 17111921
[TBL] [Abstract][Full Text] [Related]
18. Vitamin E supplementation prevents spatial learning deficits and dendritic alterations in aged apolipoprotein E-deficient mice.
Veinbergs I; Mallory M; Sagara Y; Masliah E
Eur J Neurosci; 2000 Dec; 12(12):4541-6. PubMed ID: 11122365
[TBL] [Abstract][Full Text] [Related]
19. Synaptotagmin and synaptic transmission alterations in apolipoprotein E-deficient mice.
Veinbergs I; Mante M; Jung MW; Van Uden E; Masliah E
Prog Neuropsychopharmacol Biol Psychiatry; 1999 Apr; 23(3):519-31. PubMed ID: 10378234
[TBL] [Abstract][Full Text] [Related]
20. Oral Cerebrolysin enhances brain alpha activity and improves cognitive performance in elderly control subjects.
Alvarez XA; Lombardi VR; Corzo L; Pérez P; Pichel V; Laredo M; Hernández A; Freixeiro F; Sampedro C; Lorenzo R; Alcaraz M; Windisch M; Cacabelos R
J Neural Transm Suppl; 2000; 59():315-28. PubMed ID: 10961443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
